Sol-Gel Technologies Ltd. (SLGL)
| Market Cap | 154.20M |
| Revenue (ttm) | 12.52M |
| Net Income (ttm) | -17.30M |
| Shares Out | 23.12M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,866 |
| Open | 6.64 |
| Previous Close | 6.65 |
| Day's Range | 6.25 - 6.67 |
| 52-Week Range | 6.12 - 16.69 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 17.75 (+166.1%) |
| Earnings Date | n/a |
About SLGL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is 17.75, which is an increase of 166.12% from the latest price.
News
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnec...
NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®
NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...
Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
NESS ZIONA, Israel, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...
SolGel Technologies Ltd. (SLGL) Earnings Expected to Grow: Should You Buy?
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical...
Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical...
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -75.00% and -71.55%, respectively, for the quarter ended June 2021.
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
NESS ZIONA, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...
SolGel Technologies Ltd. (SLGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SolGel Technologies Ltd. (SLGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric pat...
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical ...
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...
Sol-Gel Announces Pipeline Update and Future Development Plans
NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in th...
NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world's largest independent dermatology co...
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 63.27% and -59.15%, respectively, for the quarter ended March 2021.
Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ®
Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL
NEW YORK, April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised ...
Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and ...
SolGel Technologies Ltd. (SLGL) Moves 9.7% Higher: Will This Strength Last?
SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume.
SolGel Technologies Ltd. (SLGL) Stock Jumps 10.8%: Will It Continue to Soar?
SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume.
SolGel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020.
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively